Levonorgestrel-releasing intrauterine system treatment for endometrial hyperplasia and early endometrial cancer: a systematic review.

Background: Levonorgestrel-releasing intrauterine systems (LNG-IUS) are considered off-label and investigational in the United States for treating non-atypical endometrial hyperplasia (NAEH), atypical endometrial hyperplasia (AEH), and early-stage endometrial cancer (EC), though evidence suggests po...

Descripción completa

Detalles Bibliográficos
Publicado en:Therapeutic Advances in Reproductive Health Vol. 20; pp. 1 - 27
Autores principales: Bolling, Kristina Rosa, Suh-Burgmann, Elizabeth, Reed, Susan D., Westin, Shannon, Fassett, Michael, Wahdan, Yesmean, Lukkari-Lax, Eeva, Schoendorf, Juliane, Schoof, Nils, Moeller, Carsten, Delgado, Livia, Gill, Malia, Lorenzi, Maria, Feakins, Benjamin, Wissinger, Erika, Lee, Angie
Formato: meta analysis research systematic review tables/charts Journal Article
Publicado: Sage Publications Inc. 4/15/2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=193059604&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 193059604
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        26334941
        N9DZ
      jtl: Therapeutic Advances in Reproductive Health
      issn: 26334941
      maglogo: N
    pubinfo:
      dt: 4/15/2026
      vid: 20
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        193059604
        193059604
        193059604
        10.1177/26334941261433726
        193059604
      ppf: 1
      ppct: 26
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Levonorgestrel-releasing intrauterine system treatment for endometrial hyperplasia and early endometrial cancer: a systematic review.
      aug:
        au:
          Bolling, Kristina Rosa
          Suh-Burgmann, Elizabeth
          Reed, Susan D.
          Westin, Shannon
          Fassett, Michael
          Wahdan, Yesmean
          Lukkari-Lax, Eeva
          Schoendorf, Juliane
          Schoof, Nils
          Moeller, Carsten
          Delgado, Livia
          Gill, Malia
          Lorenzi, Maria
          Feakins, Benjamin
          Wissinger, Erika
          Lee, Angie
        affil: Conceptualization, Bayer HealthCare, 100 Bayer Boulevard, Whippany, NJ 07981, USA
      sug:
        subj:
          Intrauterine Devices
          Levonorgestrel Administration and Dosage
          Hyperplasia Drug Therapy
          Endometrial Neoplasms Drug Therapy
          Neoplasm Staging
          Treatment Outcomes
          Funding Source
          Human
          Female
          Systematic Review
          Meta Analysis
          Medline
          Embase
          Cochrane Library
          Checklists
          Odds Ratio
          Confidence Intervals
          Data Analysis Software
          Descriptive Statistics
          Pathologic Complete Response
          Female
      ab: Background: Levonorgestrel-releasing intrauterine systems (LNG-IUS) are considered off-label and investigational in the United States for treating non-atypical endometrial hyperplasia (NAEH), atypical endometrial hyperplasia (AEH), and early-stage endometrial cancer (EC), though evidence suggests potential benefit. Objectives: To summarize the available evidence regarding the use of LNG-IUS, with or without other therapies, for the treatment of NAEH, AEH, and early-stage (FIGO I/IA) EC. Design: Systematic literature review and meta-analyses. Data sources: MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Cochrane Database of Systematic Reviews (CDSR) were searched from database inception through May 2022. Methods: Data from studies reporting complete outcome definitions and study populations that were aligned with the 2014 World Health Organization (WHO) endometrial hyperplasia classification criteria or were defined as FIGO grade 1 stage I/IA EC were extracted and assessed in random-effects meta-analyses. A risk of bias assessment was completed using recommended study-design-specific tools. Results: 1085 unique records were reviewed; 80 publications were included, with data from 30 assessed in meta-analyses: NAEH, n = 14; AEH, n = 21; EC, n = 5. Complete response (CR) rates at 12 months were high: 86.3% (95% confidence interval (CI): 78.50%–91.55%; n = 342) of patients with NAEH, 83.9% (95% CI: 71.95%–91.34%; n = 196) of patients with AEH, and 51.1% (95% CI: 16.30%–84.90%; n = 20) of patients with EC. LNG-IUS was associated with significantly greater odds of CR at 12 months compared to oral progestins in NAEH and AEH populations, with odds ratios ranging from 2.16 (95% CI: 1.38–3.36) to 4.56 (95% CI: 2.57–8.09). No comparative data were available for EC. Safety information was consistent with that of approved LNG-IUS indications. Risk of bias varied across study designs. Conclusion: The findings suggest that NAEH, AEH, and early-stage (FIGO I/IA) EC can be effectively treated with LNG-IUS, with the evidence being strongest for NAEH and weakest for EC. Greater availability of LNG-IUS treatment could provide meaningful benefit to these patients. Trial registration: Not applicable. Plain language summary: Hormonal intrauterine system (IUS) treatment for thickened uterine lining and early uterine cancer: a comprehensive review This comprehensive review of published scientific studies looked at whether a type of hormonal device called a levonorgestrel-releasing intrauterine system (LNG-IUS) is effective and safe for treating abnormally thickened uterine lining and early uterine cancer. The specific uterine conditions of interest included non-atypical endometrial hyperplasia (NAEH), atypical endometrial hyperplasia (AEH), and early-stage endometrial cancer (EC). Researchers reviewed studies published up to May 2022 and identified 80 relevant articles, focusing on 30 of them for detailed analysis. A high percentage of patients had positive outcomes. In 86.3% of patients with NAEH, 83.9% of patients with AEH, and 51.1% of patients with EC, there was no evidence of disease after 12 months of treatment. The LNG-IUS was found to be more effective than oral hormone medications for treating NAEH and AEH. However, there was not enough information available to make direct comparisons for patients with EC. The safety of LNG-IUS treatment was similar to what has already been established for its approved uses. Overall, the published literature suggests that LNG-IUS is an effective treatment option for NAEH, AEH, and EC, with the strongest evidence for NAEH and the weakest evidence for EC. Greater access to this treatment could offer significant benefits to patients with these uterine conditions.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        systematic review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N